Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | MGLL | Q99685 | 14/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.40 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20695353 | 0.86 | MGLL (0.41) | USP2SMN1; SMN2MGLL | |
| SCHEMBL28751835 | 0.84 | MKNK1 (0.40) | USP2SMN1; SMN2MGLLKDM4EMAPT | |
| SCHEMBL12501315 | 0.81 | USP2 (0.47) | USP2SMN1; SMN2KDM4EMAPTTHRB | |
| SCHEMBL7010905 | 0.80 | USP2 (0.46) | USP2SMN1; SMN2KDM4EMAPTTHRB | |
| SCHEMBL20355303 | 0.78 | USP2 (0.43) | USP2SMN1; SMN2KDM4EMAPTTHRB | |
| SCHEMBL15447211 | 0.77 | DDB1 (0.47) | USP2SMN1; SMN2KDM4EMAPTTHRB | |
| SCHEMBL18319196 | 0.76 | USP2 (0.43) | USP2SMN1; SMN2KDM4EMAPTTHRB | |
| SCHEMBL7309370 | 0.75 | USP2 (0.53) | USP2SMN1; SMN2KDM4EMAPTTHRB | |
| SCHEMBL2028457 | 0.75 | DDB1 (0.45) | USP2SMN1; SMN2KDM4EMAPTTHRB | |
| SCHEMBL15798840 | 0.74 | USP2 (0.50) | USP2SMN1; SMN2KDM4EMAPTTHRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116969977-A | PAN-KRAS inhibitors | 北京华森英诺生物科技有限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-116731045-A | KRAS inhibitor, preparation method and application thereof | 北京华森英诺生物科技有限公司 | 2023-09-12 | — | — | CN | disclosed |
| EP-3727378-B1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME LLC (US) | 2023-02-22 | — | — | EP | disclosed |
| US-11179389-B2 | Purine inhibitors of human phosphatidylinositol 3-kinase delta | MERCK SHARP & DOHME CORP. (US) | 2021-11-23 | — | — | US | disclosed |
| US-11179389-B2 | Purine inhibitors of human phosphatidylinositol 3-kinase delta | MERCK SHARP & DOHME CORP. (US) | 2021-11-23 | — | — | US | disclosed |
| US-20200390760-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME CORP. (US) | 2020-12-17 | — | — | US | disclosed |
| US-20200390760-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | MERCK SHARP & DOHME CORP. (US) | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200390760-A1 | PURINE INHIBITORS OF HUMAN PHOSPHATIDYLINOSITOL 3-KINASE DELTA | PIK3CD, PIK3CA, PI4KA | USP2 3986/4885SMN1; SMN2 4497/4885MGLL 3507/4885 |
| US-11179389-B2 | Purine inhibitors of human phosphatidylinositol 3-kinase delta | PIK3CD, PIK3CA, PI4KA | USP2 3986/4885SMN1; SMN2 4497/4885MGLL 3507/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.